
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is experiencing temporary headwinds from macroeconomic factors and a specific execution issue with a top client, leading to a reduction in annual revenue guidance. However, their strong DAAP and subscription growth, as well as their unique ability to deliver targeted messaging to providers and patients, bode well for future growth and profitability. Cost actions and favorable gross margin trajectory also support their ability to maintain EBITDA guidance, making their stock trading at a discount compared to their potential.
Bears say
OptimizeRx is facing execution issues with a large client (Top 3) and economic uncertainties, resulting in lowered revenue guidance for 2026 and a negative net revenue retention rate of 110%. Additionally, the lack of managed services in the 2026 guide presents a 9% headwind to growth and the visibility on 2026 revenue remains 15-20% below the same time last year.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares